Merck Says Phase 3 KEYNOTE-A39/EV-302 Trial Met Dual Primary Endpoints Of Overall Survival And Progression-Free Survival In Certain Patients With Previously Untreated Locally Advanced or Metastatic Urothelial Cancer
Portfolio Pulse from Benzinga Newsdesk
Merck announced that its Phase 3 KEYNOTE-A39/EV-302 trial met dual primary endpoints of overall survival and progression-free survival in certain patients with previously untreated locally advanced or metastatic urothelial cancer.
September 22, 2023 | 10:01 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Merck's successful Phase 3 trial could potentially lead to a new treatment option for patients with untreated locally advanced or metastatic urothelial cancer, which may positively impact the company's stock.
The successful trial results indicate that Merck is making progress in its cancer research, which could potentially lead to a new treatment option for patients. This could increase the company's revenues and profitability, thereby positively impacting its stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100